Amneal Pharmaceuticals Inc. (AMRX) announced that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), marking the first generic version of GE Healthcare's Omnipaque (iohexol) injection. The company plans to launch the product in the first quarter of 2026.
Iohexol is a radiographic contrast agent used in a wide range of imaging procedures, including intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity applications. It is indicated for use in both adults and pediatric patients aged two weeks and older.
According to IQVIA U.S. annual sales for iohexol injection for the 12 months ended September 2025 were approximately $652 million.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.